Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367715 · ClinicalTrials.gov registry record · Phase 2
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03367715 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT03367715, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- RADIATION Radiation Therapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2022-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367715
The ClinicalTrials.gov registry entry for NCT03367715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03367715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03367715 about?
NCT03367715 is a clinical study titled "Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma". This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.
What is the current status of trial NCT03367715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-02-07. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT03367715?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT03367715?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.